Leading Chinese Biotech Firm 3SBio Lays Groundwork For Foray Into Biosimilars In U.S., E.U. Markets

BEIJING - Flush with cash from expanding earnings, leading Chinese biotech outfit 3SBio is scanning the globe for promising in-licensing deals to complement its in-house drug development pipeline and is exploring the potential to one day enter the biosimilars markets in the United States and the European Union